Adaptive methods can improve personalised medicine trials; CEO

By Nick Taylor

- Last updated on GMT

Related tags: Medicine

Conducting trials in smaller patient populations when developing personalised medicines poses challenges, such as how to recruit patients fast enough, but these can be overcome using adaptive methods, according to a CEO.

Speaking to Outsourcing-Pharma Michael Rosenberg, CEO of Health Decisions, explained that adopting adaptive methods, in both design and operations, can help improve the efficiency of trials for personalised medicines.

For instance, use of adaptive operations can help speed patient recruitment, a particular problem when conducting trials on small, specific populations, by identifying which methods are proving effective and adjusting accordingly.

Furthermore, use of adaptive design can give information on outcomes and modifiers during the course of a trial, giving companies the ability to change practices part way through the study.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars